Exelixis initiates trial for XB628 and zanzalintinib in advanced solid tumors
Exelixis is conducting a study to evaluate XB628 alone and with zanzalintinib in patients with recurrent advanced or metastatic solid tumors.
Phase III
Oncology / Combination Therapy
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The initiation of this trial by Exelixis is significant as it explores a combination therapy that could enhance treatment options for patients with advanced solid tumors. Positive outcomes could strengthen Exelixis's competitive position in the oncology market, necessitating close monitoring by pharma strategy teams.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include the determination of the maximum tolerated dose and preliminary antitumor activity results.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.